Health plans are lobbying the Trump administration to scrap a proposal dating from the final days of the Biden administration that would require Medicare and Medicaid to cover anti-obesity drugs, including GLP-1s, for weight loss. Why it matters: The final decision, expected in April, is an important barometer of which healthcare interests have President Trump's ear, since many providers, patients and drugmakers want Medicare to cover the products.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
